UNLIMITED TURBO BULL - NOVO-NORDISK B | Real-time Euronext Paris 11:04:22 05/06/2024 BST | ||
| 1.855 EUR | +10.75% |
|
| Current month | +7.72% | ||
| 1 month | +50.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 1.855 | +10.75% |
| 04/06/24 | 1.675 | +4.69% |
| 03/06/24 | 1.6 | +2.89% |
| 31/05/24 | 1.555 | -0.32% |
| 30/05/24 | 1.56 | +2.30% |
Real-time Euronext Paris
Last update June 05, 2024 at 11:04 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| 7451S | |
| ISIN | DE000SU7MR60 |
| Date issued | 30/01/2024 |
| Strike | 690 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.865 € |
|---|---|
| Lowest since issue | 0.465 € |
| Spread | 0.09 € |
| Spread % | 4.74% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Certificates
- 7451S Certificat
